NO20024587L - Forbindelser med (celle-) mÕlsökende evne - Google Patents

Forbindelser med (celle-) mÕlsökende evne

Info

Publication number
NO20024587L
NO20024587L NO20024587A NO20024587A NO20024587L NO 20024587 L NO20024587 L NO 20024587L NO 20024587 A NO20024587 A NO 20024587A NO 20024587 A NO20024587 A NO 20024587A NO 20024587 L NO20024587 L NO 20024587L
Authority
NO
Norway
Prior art keywords
caspase
compound
cytotoxic
constitutively active
connections
Prior art date
Application number
NO20024587A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024587D0 (no
Inventor
Agamemnon Antoniou Epenetos
Original Assignee
Antisoma Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antisoma Res Ltd filed Critical Antisoma Res Ltd
Publication of NO20024587D0 publication Critical patent/NO20024587D0/no
Publication of NO20024587L publication Critical patent/NO20024587L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472Cysteine endopeptidases (3.4.22)
    • C12N9/6475Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22Cysteine endopeptidases (3.4.22)
    • C12Y304/22056Caspase-3 (3.4.22.56)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22Cysteine endopeptidases (3.4.22)
    • C12Y304/22059Caspase-6 (3.4.22.59)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20024587A 2000-03-28 2002-09-25 Forbindelser med (celle-) mÕlsökende evne NO20024587L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0007343A GB2360771A (en) 2000-03-28 2000-03-28 Compounds for targeting
PCT/GB2001/001354 WO2001072336A1 (en) 2000-03-28 2001-03-28 Compounds for targeting

Publications (2)

Publication Number Publication Date
NO20024587D0 NO20024587D0 (no) 2002-09-25
NO20024587L true NO20024587L (no) 2002-11-25

Family

ID=9888460

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024587A NO20024587L (no) 2000-03-28 2002-09-25 Forbindelser med (celle-) mÕlsökende evne

Country Status (21)

Country Link
EP (1) EP1267940B1 (es)
JP (1) JP2003528156A (es)
KR (1) KR20030022782A (es)
CN (1) CN1420789A (es)
AT (1) ATE240122T1 (es)
AU (1) AU4850101A (es)
BR (1) BR0109570A (es)
CA (1) CA2402453A1 (es)
DE (1) DE60100274T2 (es)
DK (1) DK1267940T3 (es)
ES (1) ES2202287T3 (es)
GB (2) GB2360771A (es)
IL (1) IL151675A0 (es)
MX (1) MXPA02009376A (es)
NO (1) NO20024587L (es)
NZ (1) NZ521289A (es)
PL (1) PL358482A1 (es)
PT (1) PT1267940E (es)
RU (1) RU2002128746A (es)
WO (1) WO2001072336A1 (es)
ZA (1) ZA200207157B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1406137A (zh) * 2000-02-24 2003-03-26 杰南技术公司 天冬氨酸特异性半胱氨酸蛋白酶活化的前体药物治疗
US7125839B2 (en) 2002-02-07 2006-10-24 Massachusetts Institute Of Technology Anti-pathogen treatments
US9238080B2 (en) * 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
CN114173809A (zh) * 2019-04-02 2022-03-11 伊缪纯有限公司 免疫刺激组合物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
AU660297B2 (en) * 1990-11-09 1995-06-22 Stephen D. Gillies Cytokine immunoconjugates
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
AU5615594A (en) * 1992-11-13 1994-06-08 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
GB2300859B (en) * 1993-01-15 1997-06-18 Imp Cancer Res Tech Compounds comprising a target cell-specific portion and a further portion
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
US6221355B1 (en) * 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
US6379950B1 (en) * 1998-01-09 2002-04-30 Thomas Jefferson University Recombinant, active caspases and uses thereof
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities

Also Published As

Publication number Publication date
MXPA02009376A (es) 2004-05-14
AU4850101A (en) 2001-10-08
EP1267940B1 (en) 2003-05-14
DK1267940T3 (da) 2003-09-08
DE60100274D1 (de) 2003-06-18
CN1420789A (zh) 2003-05-28
ATE240122T1 (de) 2003-05-15
NO20024587D0 (no) 2002-09-25
KR20030022782A (ko) 2003-03-17
GB2360772B (en) 2002-05-22
GB0107725D0 (en) 2001-05-16
GB2360771A (en) 2001-10-03
NZ521289A (en) 2004-04-30
PL358482A1 (en) 2004-08-09
GB2360772A (en) 2001-10-03
RU2002128746A (ru) 2004-03-27
PT1267940E (pt) 2003-09-30
DE60100274T2 (de) 2004-04-01
BR0109570A (pt) 2003-01-28
CA2402453A1 (en) 2001-10-04
ZA200207157B (en) 2003-12-05
EP1267940A1 (en) 2003-01-02
GB0007343D0 (en) 2000-05-17
ES2202287T3 (es) 2004-04-01
JP2003528156A (ja) 2003-09-24
IL151675A0 (en) 2003-04-10
WO2001072336A1 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
NO20055209L (no) Peptabody for cancerbehandling
MXPA02011379A (es) Ensayo de deteccion de genes para mejorar la probabilidad de una respuesta efectiva a terapia de cancer con el antagonista erbb.
BR0308090A (pt) conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
EP1414471A4 (en) THERAPEUTIC AGENTS CONTAINING PRO-APOPTOTIC PROTEINS
IL115517A0 (en) Biologically active proteins
MXPA05013564A (es) Proteinas de fusion.
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
WO2005062977A3 (en) Prostate cancer specific internalizing human antibodies
HUP0001931A2 (hu) Kémiai vegyületek
WO2001087227A3 (en) Drug containing polymeric micelles
ATE355288T1 (de) Verbindungen und therapeutische methoden
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
NO20024587D0 (no) Forbindelser med (celle-) målsökende evne
WO1999002704A3 (en) Dual specifically phosphatase and methods of use
DE69700983D1 (de) Ligandgerichtete enzyme-prodrug therapie
WO2002094881A3 (en) Monoclonal antibody neutralising cathepsin b activity and uses thereof
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
FR2813606B1 (fr) Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques
ATE407702T1 (de) Liposomale einkapselung von alphastrahlern, und deren verwendung
WO2002079222A3 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases
PT980379E (pt) Oligonucleotidos quimericos e sua utilizacao
UA34406A (uk) Засіб для лікування розсіяного склерозу, спосіб лікування з його використанням та фармацевтична упаковка

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application